China pharmaceutical commerce recovery has yet to arrive; HSBC maintains Hold ratings on major distributors

Overview

This report evaluates the 2025 results and 2026-2028 outlook for China's pharmaceutical commerce and pharmaceutical distribution industries. HSBC believes Shanghai Pharma's performance was broadly in line with expectations, while Sinopharm came in slightly below expectations due to weaker sales growth; both companies saw marginal improvement in gross margins, but industry-wide revenue recovery remains unclear. Weak domestic recovery, pressure on the basic medical insurance system's revenues and expenditures, normalized random hospital inspections, and the impact of volume-based procurement remain the core factors suppressing growth at major distributors.

Core views

The core view is 'margin stabilization but insufficient growth momentum.' Shanghai Pharma benefited from the Hutchison acquisition and investment in its pharmaceutical business, leading to faster net profit growth in 2025, but distribution business growth has fallen back to industry levels; Sinopharm saw revenue decline year on year, with both pharmaceutical and medical device distribution remaining weak. Industry consolidation brings scale expansion and market share gains, but the assets being integrated are mostly low-margin businesses, and the pressure on receivables and inventory appears before scale benefits, making it difficult for operating efficiency improvements to fully offset medical insurance funding tightness.

Analysis framework

The report combines company earnings review, earnings forecast revisions, PEG valuation, and DCF valuation. Shanghai Pharma's A/H shares continue to be valued using the PEG method, with target P/E derived from the 2022-2024 average PEG and 2023-2028 EPS CAGR; Sinopharm continues to use a DCF model, with target price estimated based on WACC, long-term growth rate, and FX assumptions.

Methodology notes

• Valuation methodPEG

  PEG valuation is used to estimate Shanghai Pharma A/H-share target prices

  Based on Shanghai Pharma's 2022-2024 average PEG of 1.07x and 2023-2028 EPS CAGR of 11.82%, HSBC derives a target P/E of 12.7x for the A share; for the H share, the target P/E is derived as 7.0x based on a 0.6x PEG.

• Valuation methodDCF

  DCF valuation is used to estimate Sinopharm's target price

  Sinopharm's target price is based on a DCF model, with key assumptions including WACC of 8.8%, equity risk premium of 4.75%, risk-free rate of 4.25%, three-year beta of 1.05, and perpetual growth rate of 2.0%.

• Industry analysisVolume-based procurement and medical insurance pressure analysis

  VBP and medical insurance funding constraints affect distributors' revenue and margins

  The report attributes the marginal gross margin improvement to the low base from the 4Q24 volume-based procurement disruption, while also arguing that tight basic medical insurance funds, normalized hospital inspections, and volume-based procurement will continue to constrain industry growth.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Shanghai Pharma A-share 601607.CH

  Covered company / leading pharmaceutical commerce player

  Strengths

  2025 revenue was broadly in line with expectations, net profit rose on the acquisition contribution, 4Q25 gross margin increased by about 30bp year on year, and cost control was good.

  Weaknesses

  Distribution business growth slowed, with 4Q25 growth at about 3.5%; selling expenses were above expectations, and near-term growth has already been largely reflected in the market.

  Comparison

  Compared with Sinopharm, Shanghai Pharma has more visible profit growth from its pharmaceutical business and acquisition contribution, but its distribution business also faces the same weak industry recovery.

  Risks

  Slower-than-expected new drug R&D and delivery, weaker-than-expected corporate governance, and major products being unexpectedly concentrated in procurement, leading to sharp price declines.

• Shanghai Pharma H-share 2607.HK

  Covered company / Shanghai Pharma Hong Kong-listed share

  Strengths

  Shares the same fundamentals as the A share, while the H-share valuation uses a lower PEG and P/E multiple, reflecting the Hong Kong market discount.

  Weaknesses

  The HKD11.60 target price implies about 2.8% downside versus the current HKD11.94 price.

  Comparison

  The A-share target price implies about 4.2% upside, while the H-share target price implies downside; both ratings are Hold.

  Risks

  Hong Kong valuation, FX assumptions, industry growth, and corporate governance may all affect target price realization.

• Sinopharm 1099.HK

  Covered company / leading pharmaceutical distributor

  Strengths

  State-owned enterprise status helps it continue participating in market consolidation, and improvements in operating efficiency may support steady profit growth.

  Weaknesses

  2025 revenue declined 1.6% year on year, net profit rose only 1.5%, pharmaceutical and medical device distribution remained weak, and near-term revenue growth and margin repair were slower than expected.

  Comparison

  Compared with Shanghai Pharma, Sinopharm faces more direct revenue pressure, and HSBC's 2026-2028 net profit forecasts are 5%-12% below market consensus.

  Risks

  Volume-based procurement affecting medical devices and drugs more than expected, a worse-than-expected decline in cash conversion cycle leading to higher financing and credit risks, and retail business operating efficiency below expectations.

Key data

• Shanghai Pharma 2025 revenueRMB283.6bn, up 3.03% year on yearBroadly in line with HSBC's prior expectations.
• Shanghai Pharma 2025 net profitUp 25.74% year on yearMainly driven by the impact of the Hutchison acquisition on April 3, 2025.
• Shanghai Pharma 4Q25 gross margin11.7%, up 30bp year on yearThe report believes this mainly reflects stronger contribution from pharmaceutical sales and a low base.
• Shanghai Pharma target priceA share RMB18.00; H share HKD11.60Lowered from RMB18.70 and HKD11.80, respectively.
• Sinopharm 2025 revenueRMB575.2bn, down 1.6% year on yearSlightly below HSBC's prior expectations.
• Sinopharm 2025 net profitRMB7,155m, up 1.5% year on yearWeaker pharmaceutical and medical device distribution businesses weighed on performance.
• Sinopharm 2025 gross marginUp 10bp year on yearReflects a modest easing of the structural impact from volume-based procurement.
• Sinopharm target priceHKD19.50Target price unchanged, implying about 6.8% downside versus the current price.
• China distributor valuationAbout 1.1x 2027e PEGThe report believes this is consistent with the historical average and that the current valuation is fair.

Impact & implications

In terms of investment implications, the report leans more toward a defensive and fairly valued view rather than confirmation of a recovery inflection point. Leading pharmaceutical commerce companies may continue to benefit from industry consolidation, operating efficiency improvements, and new business transformation, but near-term revenue recovery and margin repair lack sufficient certainty. Investors should watch volume-based procurement intensity, medical insurance payment pressure, changes in accounts receivable days and inventory cycles, and whether commercial insurance, SPD, CSO, and innovative drug businesses can contribute new growth sources.

Risks

• Domestic pharmaceutical demand recovery is weaker than expected.
• Tight basic medical insurance balances continue to create payment and reimbursement pressure.
• Normalized random hospital inspections suppress channel and end-market sales momentum.
• Volume-based procurement has a stronger-than-expected impact on drug and medical device prices.
• Major distributors' accounts receivable days remain elevated, and cash conversion cycle improvement falls short of expectations.
• Industry consolidation mainly aggregates low-margin assets, and scale benefits take longer than expected to materialize.
• Corporate governance, equity incentives, and operating efficiency improvement fall short of expectations.

What to watch

• Whether the price cuts in the 11th round of volume-based procurement are mild.
• Whether commercial insurance promotion can ease payment pressure.
• Changes in accounts receivable days, inventory days, and cash conversion cycles for Shanghai Pharma and Sinopharm.
• Whether revenue growth from 2026 to 2028 can return to the industry's recovery track.
• Progress in new business transformation such as SPD, CSO, self-developed innovative drugs, and medical device procurement expansion.
• Sinopharm's retail business operating efficiency and realization of economies of scale.
• The impact of FX assumptions, interest-rate changes, and financing costs on valuation and cash flow.